Показано 0 из 0
Дата |
---|
02.07.2024 |
01.07.2024 |
28.06.2024 |
27.06.2024 |
26.06.2024 |
25.06.2024 |
24.06.2024 |
21.06.2024 |
20.06.2024 |
19.06.2024 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
---|---|---|---|---|---|---|---|
|
|
|
|
|
19.64
|
|
|
|
|
|
|
|
|
|
19.64
|
|
|
|
|
|
|
|
|
|
19.64
|
|
|
|
|
|
|
|
|
|
19.64
|
|
|
|
|
|
|
|
|
|
19.64
|
|
|
|
|
|
|
|
|
|
19.64
|
|
|
|
|
|
|
|
|
|
19.64
|
|
|
|
|
|
|
|
|
|
19.64
|
|
|
|
|
|
|
|
|
|
19.64
|
|
|
|
|
|
|
|
|
|
19.64
|
|
|
|
|
Exelixis, Inc. (Exelixis) is a biotechnology company engaged in developing small molecule therapies for the treatment of cancer. The Company is focusing its resources and development efforts on cabozantinib (XL184). It also has a portfolio of other compounds. Cabozantinib is the inhibitor of MET in clinical development and is being evaluated in a development program encompassing multiple cancer indications.